Amylyx Pharmaceuticals growth metrics data for the quarter ended Jun 2026. These growth metrics cover 17 quarters of results from Jun 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Growth Metrics | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Growth Ratios | |||||||||||||||||
| EBITDA Margin Growth (1y) | -0.78M | 1.59M | 0.02M | -0.01M | -0.75M | -1.82M | 0.64M | ||||||||||
| EBITDA Margin Growth (3y) | -1.01M | ||||||||||||||||
| EBITDA Margin (QoQ) | 1.56M | 0.02M | 0.00M | -234.00 | -0.00M | -0.01M | -0.73M | -1.07M | 2.46M | ||||||||
| EBIT Margin Growth (1y) | -0.78M | 1.59M | 0.02M | -0.01M | -0.75M | -1.82M | 0.64M | ||||||||||
| EBIT Margin Growth (3y) | -1.01M | ||||||||||||||||
| EBIT Margin (QoQ) | 1.56M | 0.02M | 0.00M | -234.00 | -0.00M | -0.01M | -0.73M | -1.07M | 2.46M | ||||||||
| EBT Margin Growth (1y) | -0.75M | 1.56M | 0.02M | -0.01M | -0.71M | -1.75M | 0.60M | ||||||||||
| EBT Margin Growth (3y) | -0.94M | ||||||||||||||||
| EBT Margin (QoQ) | 1.54M | 0.02M | 0.00M | -262.00 | -0.00M | -0.01M | -0.70M | -1.04M | 2.35M | ||||||||
| FCF Margin Growth (1y) | -0.52M | 1.26M | 0.02M | 682.00 | -0.65M | -1.00M | 0.93M | ||||||||||
| FCF Margin Growth (3y) | -0.26M | ||||||||||||||||
| FCF Margin (QoQ) | 1.24M | 0.02M | 0.00M | -0.00M | 0.00M | -0.00M | -0.65M | -0.35M | 1.93M | ||||||||
| Gross Margin Growth (1y) | 0.00M | 426.00 | 69.00 | 490.00 | 508.00 | 863.00 | |||||||||||
| Gross Margin (QoQ) | 0.00M | 549.00 | 171.00 | 60.00 | -355.00 | 192.00 | 592.00 | 78.00 | 0.00M | ||||||||
| Net Margin Growth (1y) | -0.75M | 1.56M | 0.02M | -0.01M | -0.71M | -1.75M | -0.40M | ||||||||||
| Net Margin Growth (3y) | -0.94M | ||||||||||||||||
| Net Margin (QoQ) | 1.54M | 0.02M | 0.00M | -213.00 | -0.00M | -0.01M | -0.70M | -1.04M | 1.35M | ||||||||
| Operating Margin Growth (1y) | -0.78M | 1.59M | 0.02M | -0.01M | -0.75M | -1.82M | 0.64M | ||||||||||
| Operating Margin Growth (3y) | -1.01M | ||||||||||||||||
| Operating Margin (QoQ) | 1.56M | 0.02M | 0.00M | -234.00 | -0.00M | -0.01M | -0.73M | -1.07M | 2.46M | ||||||||
| Return on Assets [ROA] Growth (1y)ROA Growth (1y) | 0.00M | 0.00M | 0.01M | 0.01M | 0.00M | -0.00M | -0.01M | -0.01M | -0.01M | -0.00M | 0.01M | 0.01M | 0.00M | 0.00M | |||
| Return on Assets [ROA] Growth (3y)ROA Growth (3y) | -0.00M | 128.00 | 0.01M | 0.00M | -65.00 | -0.00M | |||||||||||
| Return on Assets [ROA] (QoQ)ROA (QoQ) | 240.00 | -0.00M | 0.00M | 0.00M | 0.00M | 0.00M | 981.00 | -0.00M | -0.00M | -0.00M | -0.00M | 0.00M | 0.00M | 0.00M | -193.00 | -532.00 | -535.00 |
| Return on Capital Employed [ROCE] Growth (1y)ROCE Growth (1y) | 0.00M | 0.00M | 0.01M | 0.01M | 0.00M | -0.00M | -0.01M | -0.02M | -0.01M | -0.00M | 0.01M | 0.01M | 0.01M | 0.00M | |||
| Return on Capital Employed [ROCE] Growth (3y)ROCE Growth (3y) | -0.00M | -0.00M | 0.00M | 0.00M | -890.00 | -0.00M | |||||||||||
| Return on Capital Employed [ROCE] (QoQ)ROCE (QoQ) | 363.00 | -0.00M | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M | -0.00M | -0.00M | -0.01M | -0.00M | 0.00M | 0.00M | 0.00M | 0.00M | -643.00 | -925.00 |
| Return on Sales [ROS] Growth (1y)ROS Growth (1y) | -0.78M | 1.59M | 0.02M | -0.01M | -0.75M | -1.82M | 0.64M | -2.86M | 9.70M | 4.29M | |||||||
| Return on Sales [ROS] Growth (3y)ROS Growth (3y) | -1.01M | 4.06M | |||||||||||||||
| Return on Sales [ROS] (QoQ)ROS (QoQ) | 1.56M | 0.02M | 0.00M | -234.00 | -0.00M | -0.01M | -0.73M | -1.07M | 2.46M | -3.51M | 11.82M | -6.48M |